摘要:
The present invention relates to selection of sites of a communication system for measurement units that are for measuring a feature of wireless signals so that the location of a wireless station may be determined based on the measurement. Each measurement unit provides a measurement coverage. In the method a first set of information is defined, said first set relating to sites that are possible locations for the location measurement units and to the coverage provided by the site if it is provided with a measurement unit. A second set of information is defined that relates to signalling environment within the sites. Based on the defined first and second sets of information, a third set of information is defined, said third set associating each site with access entities of the communication system. Based on the third set of information, appropriate sites can be selected for the location measurement units.
摘要:
An approach is provided distributing content to multiple devices. Specifically, a distribution module causes, at least in part, a rendering of at least one user interface for distributing content among at least one device and one or more other devices with connectivity to the at least one device. The distribution module then causes, at least in part, one or more segmentations of the at least one user interface, wherein the one or more segmentations are associated with the at least one device, respective one or more of the one or more other devices, or a combination thereof. Next, the distribution module determines one or more interactions with the at least one user interface, the one or more segmentations, or a combination thereof to cause, at least in part, a distribution of the content.
摘要:
A filar includes an inner conductive core that is formed of a low-resistivity material such as silver having a resistivity of less than 20 μΩ per centimeter. A conductive coil is provided around the core to form a filar. This coil is formed of a biocompatible alloy or super alloy having an ultimate tensile strength (UTS) of between 150 kilo pounds per square inch (ksi) and 280 ksi at room temperature. Examples of such alloys include CoCrMo, CoFeCrMo, and CoFeNiCrMo. In one specific embodiment, the alloy is MP35N (CoNiCrMo), which may be low-titanium (“low-ti”) MP35N. One or more such filars may be included within a wire. This wire may be carried by an implantable medical apparatus such as a lead, lead extension, or catheter. The wire may electrically couple elements such as connector electrodes to conducting electrodes or sensors.
摘要:
This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID NO: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
摘要翻译:本申请涉及重组人类干扰素样蛋白。 在一个实施方案中,与天然存在的人干扰素α2b(HuIFN-α2b)相比,描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地,多核苷酸选自各自具有与SEQ ID:No.1至少93%相同的序列的多核苷酸,并且所述蛋白质选自蛋白质组,其各自具有与SEQ ID NO:至少85%相同的氨基酸序列 包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗(例如病毒性疾病和癌症)有反应的病症。
摘要:
In certain embodiments of the invention, a serializer has (a) an initial, transfer stage that transfers incoming parallel data from a relatively slow timing domain to a relatively fast timing domain and (b) a final, serializing stage that converts the parallel data into serialized data. Between the transfer stage and the serializing stage is an update stage that (i) buffers data between the initial and final stages and (ii) can be used to toggle the serializer between an N−1 operating mode (that serializes (N−1) bits of parallel data) and an N+1 operating mode (that serializes (N+1) bits of parallel data) to achieve a net N:1 gearing ratio where N is an odd integer. The serializer can be configurable to support other gearing ratios as well.
摘要:
A method is disclosed for conducting a query to transform data in a pre-existing database, the method comprising: collecting database information from the pre-existing database, the database information including inconsistent dimensional tables and fact tables; running an entity discovery process on the inconsistent dimensional tables and the fact tables to produce entity mapping tables; using the entity mapping tables to resolve the inconsistent dimensional tables into resolved dimensional tables; and running the query on a resolved database to obtain a query result, the resolved database including the resolved dimensional table.
摘要:
This application relates to recombinant human interferon-like proteins. In one embodiment a recombinant protein created by gene shuffling technology is described having enhanced anti-viral and anti-proliferative activities in comparison to naturally occurring human interferon alpha 2b (HuIFN-α2b). The invention encompasses a polynucleotide encoding the protein and recombinant vectors and host cells comprising the polynucleotide. Preferably the polynucleotide is selected from the group of polynucleotides each having a sequence at least 93% identical to SEQ ID: No. 1 and the protein is selected from the group of proteins each having an amino acid sequence at least 85% identical to SEQ ID No: 2. The proteins and compositions comprising the proteins can be used for treatment of conditions responsive to interferon therapy, such as viral diseases and cancer.
摘要翻译:本申请涉及重组人类干扰素样蛋白。 在一个实施方案中,与天然存在的人干扰素α2b(HuIFN-α2b)相比,描述了通过基因改组技术产生的重组蛋白质具有增强的抗病毒和抗增殖活性。 本发明包括编码蛋白质的多核苷酸和包含多核苷酸的重组载体和宿主细胞。 优选地,多核苷酸选自各自具有与SEQ ID:No.1至少93%相同的序列的多核苷酸,并且所述蛋白质选自蛋白质组,其各自具有与SEQ ID NO:至少85%相同的氨基酸序列 否:2.包含蛋白质的蛋白质和组合物可用于治疗对干扰素治疗(例如病毒性疾病和癌症)有反应的病症。
摘要:
A method is disclosed for conducting a query to transform data in a pre-existing database, the method comprising: collecting database information from the pre-existing database, the database information including inconsistent dimensional tables and fact tables; running an entity discovery process on the inconsistent dimensional tables and the fact tables to produce entity mapping tables; using the entity mapping tables to resolve the inconsistent dimensional tables into resolved dimensional tables; and running the query on a resolved database to obtain a query result, the resolved database including the resolved dimensional table.
摘要:
A lighting commissioning device and method including a lighting commissioning device for commissioning of a lighting device in a lighting system, the lighting commissioning device including an indication detector 142 responsive to indication from the lighting device and generating a lighting device indication signal 148, a change detector 144 responsive to the lighting device indication signal 148 and generating an indication detected signal 150, and a control unit 146 receiving the indication detected signal 150 and being operably connected to the lighting system.
摘要:
A cryosurgical system and related methods of utilizing distinct freeze and thaw fluids to selectively freeze or thaw tissue as part of a cryosurgical treatment plan. A closed loop cryosurgical system can include a control console, a cryocooler, a freeze tank, a thaw tank as well as fluid supply and fluid return lines operably interconnecting one or more cryoprobes with the freeze and thaw tank. At the direction of the control console, the cryocooler is used to cool a freeze fluid in the freeze tank while a heating element in the thaw tank is used to head a thaw fluid in the thaw tank. By using distinctly controlled reservoirs of freeze and thaw fluid, the cryosurgical system is able to quickly cycle back and forth between freeze and thaw cycles conducted as part of a cryosurgical treatment.